Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04132817
Recruitment Status : Recruiting
First Posted : October 21, 2019
Last Update Posted : September 10, 2020
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response. This study utilizes an innovative clinical trial design to determine the safety, tolerability, pharmacodynamic activity and efficacy of targeting multiple, distinct combination regimens that modulate several immune and non-immune mechanisms by escalating the number of therapies administered.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: Nivolumab Biological: Ipilimumab Drug: Nab-paclitaxel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 135 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast Cancer
Actual Study Start Date : December 18, 2019
Estimated Primary Completion Date : August 15, 2024
Estimated Study Completion Date : September 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Group A Target class A-1: Nivolumab+nab-paclitaxel
The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
Biological: Nivolumab
specified dose on specified days

Drug: Nab-paclitaxel
specified dose on specified days

Experimental: Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab
The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
Biological: Nivolumab
specified dose on specified days

Biological: Ipilimumab
specified dose on specified days

Drug: Nab-paclitaxel
specified dose on specified days

Experimental: Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab
The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
Biological: Nivolumab
specified dose on specified days

Biological: Ipilimumab
specified dose on specified days

Drug: Nab-paclitaxel
specified dose on specified days




Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs) [ Time Frame: Up to 3 years ]
  2. Incidence of Serious Adverse Events (SAEs) [ Time Frame: Up to 3 years ]
  3. Incidence of AEs leading to dose and asset limiting toxicity (DALT) [ Time Frame: 8 weeks following initial dose ]
  4. Incidence of AEs leading to discontinuation [ Time Frame: Up to 3 years ]
  5. Incidence of laboratory abnormalities [ Time Frame: Up to 3 years ]

Secondary Outcome Measures :
  1. Change from baseline in programmed cell death receptor-ligand 1 (PD-L1) by immunohistochemistry (IHC) [ Time Frame: Day 0, Day 22, Day 50 ]
  2. Objective Response Rate (ORR) [ Time Frame: 24 weeks ]
  3. Median duration of response (mDOR) [ Time Frame: 24 weeks ]
  4. Progression-free survival rate (PFSR) [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Histological and cytological confirmation of adenocarcinoma of the breast
  • Documented HER2 negative and estrogen receptor (ER) positive status of primary or metastatic tumor tissue using the most recently assessed tumor specimen, according to the local laboratory parameters
  • ER negativity is defined as < 1% of tumor cells expressing hormonal receptors via IHC analysis
  • At least one measurable lesion, as per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] that can be accurately assessed at baseline and is suitable for repeated assessment by computed tomography (CT) or magnetic resonance imaging (MRI)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Women and Men must agree to follow specific methods of contraception, if applicable, while participating in the trial

Exclusion Criteria:

  • Allergy or hypersensitivity to any study drugs or their excipients
  • Any other sound medical, psychiatric and/or social reason as determined by the investigator
  • Active, known, or suspected autoimmune disease or immune-related diseases
  • History of unstable or deteriorating cardiac disease within the previous 12 months prior to screening
  • Prior therapy with anti-programmed death 1 (PD-1), anti-programmed death-ligand 1 (PD-L1) or anti-Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) class antibody
  • Any major surgery within 4 weeks of the first dose of study treatment

Other protocol-defined inclusion/exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04132817


Contacts
Layout table for location contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.

Locations
Layout table for location information
United States, California
Local Institution Not yet recruiting
Los Angeles, California, United States, 90033
Contact: Site 0011         
Local Institution Not yet recruiting
Newport Beach, California, United States, 92663
Contact: Site 0014         
Local Institution Not yet recruiting
Sacramento, California, United States, 95817
Contact: Site 0003         
Local Institution Not yet recruiting
San Francisco, California, United States, 94115
Contact: Site 0006         
United States, Colorado
Local Institution Not yet recruiting
Aurora, Colorado, United States, 80045
Contact: Site 0009         
United States, Connecticut
Local Institution Not yet recruiting
New Haven, Connecticut, United States, 06520
Contact: Site 0001         
United States, Illinois
Local Institution Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Site 0015         
United States, Missouri
Washington University School Of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Leonel Hernandez Aya, Site 0002    314-362-9679      
United States, New York
Local Institution Not yet recruiting
New York, New York, United States, 10016
Contact: Site 0008         
Local Institution Not yet recruiting
Uniondale, New York, United States, 11553
Contact: Site 0004         
United States, Ohio
Local Institution Not yet recruiting
Cleveland, Ohio, United States, 44195
Contact: Site 0012         
United States, Pennsylvania
Local Institution Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Site 0005         
United States, Texas
Local Institution Not yet recruiting
Dallas, Texas, United States, 75390-9236
Contact: Site 0010         
Local Institution Not yet recruiting
San Antonio, Texas, United States, 78229
Contact: Site 0013         
United States, Utah
Local Institution Not yet recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site 0007         
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT04132817    
Other Study ID Numbers: CA048-001
First Posted: October 21, 2019    Key Record Dates
Last Update Posted: September 10, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Nivolumab
Ipilimumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological